

## Supplementary data

**Supplementary Table 1. Antithrombotic therapy.**

Antithrombotic therapy	Dual ProGlide (n=437)	ProGlide + FemoSeal (n=437)	p-value
<b>Baseline</b>			
Antiplatelet monotherapy	228 (52.2%)	205 (46.9%)	0.12
Dual antiplatelet therapy	56 (12.8%)	40 (9.2%)	0.08
Oral anticoagulation	187 (42.8%)	176 (40.3%)	0.43
Vitamin K antagonists	48 (11.0%)	32 (7.3%)	0.06
DOAC	139 (32.0%)	144 (33.0%)	0.94
Oral anticoagulation + single antiplatelet therapy	58 (13.3%)	35 (8.0%)	<b>0.011</b>
Triple therapy*	13 (3.0%)	11 (2.5%)	0.68
<b>Discharge</b>			
Antiplatelet monotherapy	102 (23.3%)	125 (28.6%)	0.12
Dual antiplatelet therapy	232 (53.1%)	230 (52.6%)	0.90
Oral anticoagulation	208 (47.6%)	207 (47.4%)	0.74
Vitamin K antagonists	44 (10.1%)	25 (5.7%)	<b>0.014</b>
DOAC	164 (37.5%)	182 (41.6%)	0.30
Oral anticoagulation + single antiplatelet	76 (17.4%)	66 (15.1%)	0.29
Triple therapy	33 (7.6%)	26 (5.9%)	0.30

Values are depicted as no. (percentage of total no.)

\*Triple therapy: dual antiplatelet therapy and oral anticoagulation

DOAC: direct oral anticoagulant

**Supplementary Table 2. Details of vascular complications.**

<b>Variable</b>	<b>Dual ProGlide (n=437)</b>	<b>ProGlide + FemoSeal (n=437)</b>	<b>p-value</b>
Closure device failure	12 (2.7%)	4 (0.9%)	<b>0.044</b>
Hematoma/bleeding	48 (11.0%)	15 (3.4%)	<b>&lt;0.001</b>
Pseudoaneurysm	14 (3.2%)	15 (3.4%)	0.85
Thrombin injection of pseudoaneurysm	6 (1.4%)	10 (2.3%)	0.31
AV-fistula	3 (0.7%)	3 (0.7%)	1
Limb ischaemia	3 (0.7%)	0	0.25
Dissection	1 (0.2%)	1 (0.2%)	1
Unplanned surgery	14 (3.2%)	3 (0.7%)	<b>0.007</b>
Unplanned endovascular treatment	4 (0.9%)	1 (0.2%)	0.37
Bailout MANTA VCD	1 (0.2%)	3 (0.7%)	0.62
Intestinal ischaemia	1 (0.2%)	0	1

Values are depicted as no. (percentage of total no.).

AV-fistula: arteriovenous fistula; VCD: vascular closure device


**Supplementary Table 3. Predictors of the primary endpoint.**

	Univariable analysis		Multivariable analysis	
	OR (95% CI)	p-value	OR (95% CI)	p-value
Age	1.04 (1.00-1.07)	<b>0.041</b>	1.04 (1.00-1.08)	<b>0.049</b>
GFR	0.99 (0.98-1.00)	0.11		
Baseline haemoglobin	0.88 (0.7-0.98)	<b>0.026</b>	0.89 (0.79-1.01)	0.06
Body mass index	0.98 (0.94-1.03)	0.39		
COPD	1.43 (0.78-2.64)	0.25		
PAD	0.81 (0.40-1.67)	0.57		
Oral anticoagulation	1.34 (0.88-2.04)	0.18		
Female sex	1.28 (0.84-1.94)	0.25		
ProGlide+FemoSeal	0.25 (0.15-0.41)	<b>&lt;0.001</b>	0.24 (0.14-0.39)	<b>&lt;0.001</b>
Coronary artery disease	2.18 (1.36-3.51)	<b>0.001</b>	2.28 (1.40-3.71)	<b>0.001</b>
LVEF	0.99 (0.97-1.01)	0.23		
Diabetes mellitus	1.16 (0.73-1.84)	0.54		
Tertile 1	1.25 (0.76-2.05)	0.38		
Tertile 2*	Reference			
Tertile 3	0.86 (0.50-1.47)	0.57		

\*Both study groups were divided into tertiles based on the time of intervention and tertile 2 was selected as reference for logistic regression analysis.

COPD: chronic pulmonary obstructive disease; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; OR: odds ratio; PAD: peripheral artery disease

**Supplementary Figure 1.** Standardised mean differences before and after propensity score matching.



Love plot of standardised mean differences before and after propensity score matching. COPD: chronic obstructive pulmonary disease; LV: left ventricular; STS: Society of Thoracic Surgeons